Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.73 |
| ▸ | TNF | P01375 | 2/20 | 0.70 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | KCNA5 | P22460 | 7/20 | 0.65 |
| ▸ | JAK2 | O60674 | 2/20 | 0.65 |
| ▸ | CDK2 | P24941 | 2/20 | 0.65 |
| ▸ | TYK2 | P29597 | 2/20 | 0.65 |
| ▸ | GSK3B | P49841 | 2/20 | 0.65 |
| ▸ | JAK3 | P52333 | 2/20 | 0.65 |
| ▸ | BTK | Q06187 | 2/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.65 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.65 |
| ▸ | IGF1R | P08069 | 1/20 | 0.65 |
| ▸ | PIM1 | P11309 | 1/20 | 0.65 |
| ▸ | SRC | P12931 | 1/20 | 0.65 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.65 |
| ▸ | JAK1 | P23458 | 1/20 | 0.65 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.65 |
| ▸ | FLT4 | P35916 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3385334 | 0.91 | ESR1 (0.61) | ESR1TNFNOD1MAPK1KCNA5 | |
| SCHEMBL2368912 | 0.87 | TNF (0.67) | ESR1TNFNOD1MAPK1KCNA5 | |
| SCHEMBL2368545 | 0.86 | TNF (0.70) | ESR1TNFNOD1MAPK1KCNA5 | |
| SCHEMBL3382742 | 0.86 | TNF (0.70) | ESR1TNFNOD1MAPK1KCNA5 | |
| SCHEMBL2368773 | 0.84 | ESR1 (0.70) | ESR1TNFNOD1MAPK1KCNA5 | |
| SCHEMBL20665775 | 0.84 | TNF (0.67) | ESR1TNFNOD1MAPK1KCNA5 | |
| SCHEMBL2368584 | 0.84 | TNF (0.67) | ESR1TNFNOD1MAPK1KCNA5 | |
| SCHEMBL3383435 | 0.84 | TNF (0.67) | ESR1TNFNOD1MAPK1KCNA5 | |
| SCHEMBL31336894 | 0.84 | TNF (0.67) | ESR1TNFNOD1MAPK1KCNA5 | |
| SCHEMBL3381249 | 0.84 | TNF (0.66) | ESR1TNFNOD1MAPK1KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249155-B2 | Thieno [2, 3-D] pyrimidine derivatives and their use to treat arrhythmia | XENTION LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-9249155-B2 | Thieno [2, 3-D] pyrimidine derivatives and their use to treat arrhythmia | XENTION LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-9249155-B2 | Thieno [2, 3-D] pyrimidine derivatives and their use to treat arrhythmia | XENTION LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| EP-2694518-B1 | THIENO[2,3-D]PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA | XENTION LTD (GB) | 2015-10-07 | — | — | EP | disclosed |
| US-20140206703-A1 | THIENO [2, 3-D] PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA | XENTION LIMITED (GB) | 2014-07-24 | — | — | US | disclosed |
| US-20140206703-A1 | THIENO [2, 3-D] PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA | XENTION LIMITED (GB) | 2014-07-24 | — | — | US | disclosed |
| US-20140206703-A1 | THIENO [2, 3-D] PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA | XENTION LIMITED (GB) | 2014-07-24 | — | — | US | disclosed |
| EP-2694518-A1 | THIENO [2, 3 -D]PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA | Xention Limited (GB) | 2014-02-12 | — | — | EP | disclosed |
| CN-1823071-B | Thienopyrimidine derivatives as potassium channel inhibitors | XENTION DISCOVERY LTD | 2012-12-19 | — | — | CN | disclosed |
| WO-2012131379-A1 | THIENO [2, 3 -D] PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA | XENTION LIMITED (GB) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012131379-A1 | THIENO [2, 3 -D] PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA | XENTION LIMITED (GB) | 2012-10-04 | — | — | WO | disclosed |
| US-8022076-B2 | Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents | XENTION LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| EP-1641803-B3 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2010-12-08 | — | — | EP | disclosed |
| EP-1641803-B1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2009-03-18 | — | — | EP | disclosed |
| CN-1823071-A | Thienopyrimidine derivatives as potassium channel inhibitors | XENTION DISCOVERY LTD (GB) | 2006-08-23 | — | — | CN | disclosed |
| EP-1641803-A1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Xention Discovery Limited (GB) | 2006-04-05 | — | — | EP | disclosed |
| US-20050026935-A1 | Compounds | XENTION DISCOVERY LTD. | 2005-02-03 | — | — | US | disclosed |
| WO-2004111057-A1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION DISCOVERY LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206703-A1 | THIENO [2, 3-D] PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA | KCNJ2, KCNH2, KCNH1 | ESR1 4466/4885TNF 4772/4885NOD1 1470/4885 |
| US-20050026935-A1 | Compounds | KCNJ11, KCNJ1, KCNH1 | ESR1 4494/4885TNF 2689/4885NOD1 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.